United Pharm (KO:033270) — Market Cap & Net Worth
Market Cap & Net Worth: United Pharm (033270)
United Pharm (KO:033270) has a market capitalization of $182.43 Million (₩269.19 Billion) as of June 17, 2026. Listed on the KO stock exchange, this Korea-based company holds position #17018 globally and #671 in its home market, demonstrating a 6.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying United Pharm's stock price ₩18640.00 by its total outstanding shares 14441635 (14.44 Million). Review 033270 liabilities breakdown to assess the company's total debt and financial obligations.
United Pharm Market Cap History: 2015 to 2026
United Pharm's market capitalization history from 2015 to 2026. Data shows growth from $153.52 Million to $182.43 Million (0.51% CAGR).
United Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how United Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
United Pharm's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.00x
United Pharm's market cap is 0.00 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $165.47 Million | $176.91 Billion | $19.51 Billion | 0.00x | 0.01x |
| 2017 | $275.22 Million | $197.02 Billion | $27.86 Billion | 0.00x | 0.01x |
| 2018 | $210.55 Million | $211.94 Billion | $31.67 Billion | 0.00x | 0.01x |
| 2019 | $171.40 Million | $221.31 Billion | $30.92 Billion | 0.00x | 0.01x |
| 2020 | $623.45 Million | $215.95 Billion | $26.61 Billion | 0.00x | 0.02x |
| 2021 | $448.14 Million | $221.04 Billion | $28.65 Billion | 0.00x | 0.02x |
| 2022 | $218.94 Million | $262.52 Billion | $45.28 Billion | 0.00x | 0.00x |
| 2023 | $264.25 Million | $278.94 Billion | $48.26 Billion | 0.00x | 0.01x |
| 2024 | $178.22 Million | $288.71 Billion | $32.45 Billion | 0.00x | 0.01x |
| 2025 | $186.64 Million | $288.76 Billion | $38.31 Billion | 0.00x | 0.00x |
Competitor Companies of 033270 by Market Capitalization
Companies near United Pharm in the global market cap rankings as of June 17, 2026.
Key companies related to United Pharm by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
United Pharm Historical Marketcap From 2015 to 2026
Between 2015 and today, United Pharm's market cap moved from $153.52 Million to $ 182.43 Million, with a yearly change of 0.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩182.43 Million | -2.25% |
| 2025 | ₩186.64 Million | +4.72% |
| 2024 | ₩178.22 Million | -32.56% |
| 2023 | ₩264.25 Million | +20.69% |
| 2022 | ₩218.94 Million | -51.14% |
| 2021 | ₩448.14 Million | -28.12% |
| 2020 | ₩623.45 Million | +263.74% |
| 2019 | ₩171.40 Million | -18.59% |
| 2018 | ₩210.55 Million | -23.50% |
| 2017 | ₩275.22 Million | +66.32% |
| 2016 | ₩165.47 Million | +7.79% |
| 2015 | ₩153.52 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of United Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $182.43 Million USD |
| MoneyControl | $182.43 Million USD |
| MarketWatch | $182.43 Million USD |
| marketcap.company | $182.43 Million USD |
| Reuters | $182.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About United Pharm
Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to app… Read more